CALLISTO REPORTS DATA ON ATIPRIMOD

Callisto Pharmaceuticals has reported data on a clinical trial of its anticancer drug Atiprimod in multiple myeloma patients.

The Phase I/IIa clinical trial in relapsed or refractory multiple myeloma patients was conducted at four clinical sites in the U.S. The trial tested escalating dosages of Atiprimod and the drug was generally well-tolerated in this heavily treated group of patients. Two patients with rapidly rising serum M proteins -- a measure of tumor burden -- showed a transient but clear M protein reduction.